NCT03656835Active, not recruiting
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
A Pilot Study of Nanochip Technology for Monitoring Treatment Response and Detection of Relapse in Patients With Diffuse Large B-Cell Lymphoma
Source: ClinicalTrials.gov · Last updated 6 Aug 2026
Brief summary (registry, in English)
This trial studies how well nanochip technology (immuno-tethered lipoplex nanoparticle \[ILN\] biochip) works in monitoring treatment response and in detecting relapse in participants with diffuse large B-cell lymphoma. Finding genetic markers for diffuse large B-cell lymphoma may help identify participants with this disease and help predict the outcome of treatment. It is not yet known how well ILN biochip-based testing monitors treatment response or detects relapse in participants with diffuse large B-cell lymphoma.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 73 (actual)
- First submitted
- 30 Aug 2018
- Start date
- 26 Sept 2018
- Primary completion date
- 20 Nov 2024
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT03656835
What you commit to
- Study type: Interventional
- Participants enrolled: 73
- From 26 Sept 2018 to the primary completion date, 20 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participating in other clinical trial/ receiving experimental therapy.
Other illness
- Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation.
Lab values
- Pregnancy (positive serum or urine pregnancy test) or breast feeding.
Other
- Transformed lymphomas.
- DLBCL with leukemic presentation.
- Primary central nervous system (CNS) lymphoma.
Who the study is looking for
- Histologically confirmed treatment naive DLBCL. Subtypes including high grade B-cell lymphoma, not otherwise specified (NOS) and de-novo DLBCL including germinal center B-cell type (GCB) and non-GCB subtypes.
- Intent to receive entire care (treatment and follow-up) at Ohio State University (OSU).
- Receiving treatment with curative intent.
- Receiving planned 6 cycles of chemotherapy.
- Ability to consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ohio State University Comprehensive Cancer Center Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.